Folic Acid and Omega -3 Fatty Acid Supplementation in Depressed Older Adults
This study has been completed.
Sponsor:
Prof. RH Belmaker
Collaborator:
The S. Daniel Abraham International Center for Health and Nutrition
Information provided by (Responsible Party):
Prof. RH Belmaker, Beersheva Mental Health Center
ClinicalTrials.gov Identifier:
NCT00480207
First received: May 28, 2007
Last updated: November 5, 2012
Last verified: November 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Our specific aim is to determine the impact of folic acid and omega-3 supplementation on the severity of depressive symptoms among depressed adults aged 65 and above.
| Condition | Intervention | Phase |
|---|---|---|
|
Depression |
Dietary Supplement: folic acid Dietary Supplement: omega-3 Dietary Supplement: vit B12 Other: folic acid placebo Other: omega-3 placebo |
Phase 2 Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Outcomes Assessor) Primary Purpose: Supportive Care |
| Official Title: | Randomized Double-blind Controlled Clinical Trial to Assess the Impact of Folic Acid and Omega-3 Fatty Acids Supplementation on the Severity of Depressive Symptoms in Older Adults With Identified Depression |
Resource links provided by NLM:
Drug Information available for:
Folic acid
Cyanocobalamin
Vitamin B Complex
Hydroxocobalamin
Omega-3 Fatty Acids
U.S. FDA Resources
Further study details as provided by Beersheva Mental Health Center:
Primary Outcome Measures:
- the severity of depressive symptoms [ Time Frame: baseline, 4th , 8th and 12th week ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- cognitive status [ Time Frame: baseline, 4th, 8th, and 12th week ] [ Designated as safety issue: No ]
- nutritional status [ Time Frame: baseline and end of study ] [ Designated as safety issue: No ]
- possible side effects [ Time Frame: baseline, 4th, 8th, and 12th week ] [ Designated as safety issue: No ]
| Enrollment: | 15 |
| Study Start Date: | May 2007 |
| Study Completion Date: | October 2008 |
| Primary Completion Date: | October 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: omega-3, folic acid, vitB12
folic acid (1600 mcg per day), and omega-3 (2000 mg per day: active docosahexaenoic acid (DHA) and eicosapentanoic acid (EPA), proportion 1:1), vitamin B12 (1000 mcg per day)
|
Dietary Supplement: folic acid Dietary Supplement: omega-3 Dietary Supplement: vit B12 |
|
Experimental: omega-3, folic acid placebo, vit B12
omega-3,folic acid placebo (starch), vitamin B12 (1000 mcg per day)
|
Dietary Supplement: omega-3 Dietary Supplement: vit B12 Other: folic acid placebo |
|
Experimental: omega-3 placebo, folic acid, vit B12
folic acid, omega-3 placebo(canola oil),vitamin B12 (1000 mcg per day)
|
Dietary Supplement: folic acid Dietary Supplement: vit B12 Other: omega-3 placebo |
|
Experimental: omega-3 placebo, folic acid placebo, vit B12
omega-3 placebo (canola oil),folic acid placebo (starch), vitamin B12 (1000 mcg per day)
|
Dietary Supplement: vit B12 Other: folic acid placebo Other: omega-3 placebo |
Eligibility| Ages Eligible for Study: | 65 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Age 65+ (year of birth -1942 or below)
- Depression (as defined by the DSM-IV diagnostic criteria for depression: major or minor depression or dysthymia)
Exclusion Criteria:
- Co-existing psychiatric disorder (except anxiety disorders)
- Moderate and severe cognitive impairment
- Current treatment with anticoagulants, antithrombotics and fibrinolytics
- Current severe angina with exertion
- Chronic renal insufficiency
- Liver cirrhosis
- Alcohol or drug abuse
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00480207
Locations
| Israel | |
| Mental Health Center | |
| Beer-Sheva, Israel | |
Sponsors and Collaborators
Prof. RH Belmaker
The S. Daniel Abraham International Center for Health and Nutrition
Investigators
| Study Director: | Danit R Shahar, RD PhD | Ben-Gurion University of the Negev |
| Principal Investigator: | Alex Palatnik, MD | Beersheva Mental Health Center |
| Principal Investigator: | Larissa German, MD, MMedSc | The S. Daniel Abraham International Center for Health and Nutrition |
More Information
No publications provided
| Responsible Party: | Prof. RH Belmaker, Beersheva Mental Health Center |
| ClinicalTrials.gov Identifier: | NCT00480207 History of Changes |
| Other Study ID Numbers: | ICHN-4413 |
| Study First Received: | May 28, 2007 |
| Last Updated: | November 5, 2012 |
| Health Authority: | Israel: Ethics Commission |
Additional relevant MeSH terms:
|
Depression Depressive Disorder Behavioral Symptoms Mood Disorders Mental Disorders Folic Acid Vitamin B Complex Hydroxocobalamin Vitamin B 12 |
Hematinics Vitamins Micronutrients Growth Substances Physiological Effects of Drugs Pharmacologic Actions Hematologic Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 23, 2013